Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration

Xiaoyu Li^{1,3}, Yatender Kumar^{1,2,4},
Hans Zempel^{1,2,4}, Eva-Maria Mandelkow^{1,2},
Jacek Biernat^{1,2} and
Eckhard Mandelkow^{1,2,*}

¹Max-Planck-Unit for Structural Molecular Biology, c/o DESY, Hamburg, Germany and ²German Center for Neurodegenerative Diseases (DZNE) and CAESAR, Ludwig-Erhard-Allee 2, Bonn, Germany

Missorting of Tau from axons to the somatodendritic compartment of neurons is a hallmark of Alzheimer's disease, but the mechanisms underlying normal sorting and pathological failure are poorly understood. Here, we used several Tau constructs labelled with photoconvertible Dendra2 to analyse its mobility in polarized neurons. This revealed a novel mechanism of sorting—a retrograde barrier in the axon initial segment (AIS) operating as cellular rectifier. It allows anterograde flow of axonal Tau but prevents retrograde flow back into soma and dendrites. The barrier requires binding of Tau to microtubules but does not require F-actin and thus is distinct from the sorting of membrane-associated proteins at the AIS. The barrier breaks down when Tau is phosphorylated in its repeat domain and detached from microtubules, for example, by the kinase MARK/Par1. These observations link the pathological hallmarks of Tau missorting and hyperphosphorylation in neurodegenerative diseases.

The EMBO Journal (2011) 30, 4825–4837. doi:10.1038/emboj.2011.376; Published online 18 October 2011

Subject Categories: neuroscience; molecular biology of disease

Keywords: axon initial segment; microtubules; neuronal polarization; Tau protein

Introduction

An early sign of neurodegeneration in Alzheimer's disease is the missorting of Tau protein. In normal mature neurons, it has a mostly axonal distribution (Binder *et al*, 1985; Kosik and Finch, 1987; Migheli *et al*, 1988; Mandell and Banker, 1995), but in disease it appears in the somatodendritic compartment. This occurs before Tau aggregation and correlates with the incipient loss of synapses (Coleman and Yao,

2003; Ballatore *et al*, 2007; Haass and Selkoe, 2007; Pimplikar *et al*, 2010). There has been a debate on the causes of the polarized distribution of microtubule-associated proteins (MAPs) in mature neurons, notably axonal Tau and somatodendritic MAP2. Suggested contributing factors include the preferential routing of Tau or MAP2 mRNAs towards their appropriate compartment (Garner *et al*, 1988; Aronov *et al*, 2002), selective protection of Tau or MAP2 protein against degradation, and directional cues based on the interplay of microtubules, motors, and cargo (Hirokawa *et al*, 1996; Nakata and Hirokawa, 2003; Konishi and Setou, 2009). The sorting of Tau can break down in abnormal situations, for example, following excitotoxicity, cell stress, or exposure to amyloid- β peptide (Mattson, 2004; Roberson *et al*, 2007; Zempel *et al*, 2010). This causes the accumulation of Tau in cell bodies and dendrites and heralds the gradual pathological aggregation. Considering Tau's role in the disease process it would be important to gain a detailed understanding of the sorting pathway: How does it function in normal neurons? What causes it to break down in disease? Where does the missorted dendritic Tau come from, what is its fate?

The establishment of polarity in a neuron is essential for its function. It involves cytoskeletal fibres, notably microtubules and motor proteins of the kinesin superfamily (KIFs) for selective long-haul delivery of cargoes to somatodendritic and axonal compartments (e.g., dendritic neurotransmitter receptors or axonal synaptic vesicles; Burack *et al*, 2000; Lazarov *et al*, 2007; Hirokawa *et al*, 2010; Scott *et al*, 2011). A further element in maintaining polarity is the buildup of selective barriers (Ledesma and Dotti, 2003; Witte and Bradke, 2008). The best-known example for neurons is the axon initial segment (AIS), located just beyond the axon hillock. It has been characterized as an F-actin-based diffusion barrier for membrane-associated proteins and lipids, and for large (>70 kDa) cytosolic particles (Winckler *et al*, 1999; Nakada *et al*, 2003; Kole *et al*, 2008; Song *et al*, 2009).

Because of the key role of Tau in AD, we and others studied tau transport, diffusion, and MT binding in the axon by GFP-tagged proteins and FRAP (Samsonov *et al*, 2004; Konzack *et al*, 2007; Weissmann *et al*, 2009). Rapid diffusion appears to be a major mechanism for axonal Tau distribution in the short-to-intermediate range, while microtubule-dependent transport of Tau dominates over long distances. Here, we describe a new approach, photoconversion of Tau tagged with Dendra2, to directly visualize and compare the movement of different Tau variants over long distances in differentiated cortical neurons. This revealed a novel barrier mechanism that allows Tau to enter the axon but prevents it from flowing back to the somatodendritic compartment. We show that this barrier is uniquely localized in the same initial segment as the actin-based barrier of membrane components, but it depends on microtubules rather than F-actin and is regulated by Tau phosphorylation.

*Corresponding author. Max-Planck-Unit for Structural Molecular Biology, c/o DESY, Notkestrasse 85, Hamburg, 22607 Germany. Tel.: +49 40 8998 2810; Fax: 49 40 8971 6822;

E-mail: mand@mpasmb.desy.de and mandelkow@dzne.de

³Present address: Olympus Soft Imaging Solutions GmbH, Johann-Krane-Weg 39, 48149 Münster, Germany

⁴These authors contributed equally to this work

Results

Tau diffuses rapidly in neurons, but is restrained by a retrograde barrier in the initial axon

One of the enigmas of Tau in AD is its early redistribution from axons into the somatodendritic compartments. This begs two questions: how is Tau sorted into axons but not into dendrites, and why does it stay in axons in spite of its ability to diffuse rapidly? To study the redistribution of Tau, a common approach is to transfect neurons with GFP-tagged Tau into cells and then observe its redistribution after photo-bleaching (Samsonov *et al*, 2004; Konzack *et al*, 2007). In this approach, a bleached zone must be observed against a bright background, which limits the signal/noise. To overcome these limitations, we have employed new photoconvertible variants of GFP that enable one to observe the overall distribution at any time point, and then, after photoconversion in a defined region, reveal the spreading with high contrast, in spite of an apparent steady state. We chose Dendra2 which is monomeric (230 residues), highly photo-stable, matures rapidly at 37°C and displays bright fluorescence before and after photoconversion (Gurskaya *et al*, 2006; Gauthier and Brandt, 2010). An overview figure depicting the raw data and ratiometric analysis before and after photoconversion is shown in Supplementary Figure S1, illustrating a photoconversion efficiency of >60% in our experiments. When Dendra2 is transfected by lipofectamine into mature rat cortical neurons (7–11 DIV), the protein becomes visible in the cell body by its intrinsic green fluorescence (Figure 1A). In Figure 1B–D, Dendra2 is photoconverted from green to red fluorescence by irradiation at 405 nm in the cell body, and its spreading can be traced in real time (Figure 1C and D). Within seconds, Dendra2 diffuses into the proximal cell processes, and within minutes it appears along the length of dendrites and axons that can be distinguished by their length, diameter, and brightness (Figure 1D; Supplementary Movie S1). The rate of spreading is roughly consistent with the free diffusion of monomeric Dendra2 in the cytosol ($D \sim 25 \mu\text{m}^2/\text{s}$, for details see Konzack *et al*, 2007).

Figure 1E–H shows the same type of experiment with full-length human Tau (441 residues, '2N4R'), N-terminally fused to Dendra2 (688 aa residues, including a 17 aa linker, construct termed Tau^{D2}; Figure 1, top). As expected from the higher mass, Tau^{D2} spreads more slowly than Dendra2, but also fills dendrites and axons within ~48 h, as seen either by the green fluorescence of Dendra2 or by immunostaining. This behaviour is unexpected since mature neurons possess a sorting machinery that routes Tau into axons but not into dendrites (Binder *et al*, 1985; Mandell and Banker, 1995), and indeed endogenous rat Tau is sorted axonally if expressed alone (see below). On the other hand, overexpression or microinjection of Tau is known to overwhelm the sorting machinery so that Tau becomes ubiquitous in neurons (Hirokawa *et al*, 1996), as is the case here (Figure 1E). When photoconverting the exogenous Tau^{D2} in the cell body, the protein spreads gradually throughout the neuron, but again the rate is much slower than that of Dendra2 alone (~20-fold), and there is a preferential filling of axons first (Figure 1F–H). The arrival of photoactivated Tau^{D2} was monitored in selected regions of interest, for example, ~150 μm from the soma (Figure 1H, ROI2). In this case, it took ~70 min for Tau^{D2} to redistribute from the soma to the

examined area (Figure 1I; Supplementary Movie S2). Thus, this method provides a direct visualization of the dynamics of Tau in neurons.

Since the above observations suggested that the sorting machinery of neurons was still functional, in spite of a background of unsorted Tau, we began a systematic investigation of the transfer of Tau^{D2} and Dendra2 (as control) between different regions of mature neurons. Figure 2A1 illustrates part of an axon ~60 μm from the soma of a Dendra2-transfected neuron (ROI1). Photoconverted Dendra2 redistributed rapidly into the distal axon and somatodendritic compartment (Figure 2A3). In these neurons, a homogeneous distribution of fluorescence was reached across the AIS (Figure 2A2 and A4, intensity profiles at $t = 1$ and 5 min; Supplementary Movie S3).

When performing this experiment with Tau^{D2}, a very different picture emerged: the photoconverted Tau^{D2} travelled without hindrance to the distal axon; but was prevented from redistributing towards the somatodendritic compartment (Figure 2B1 and B3). An intensity gradient of photoconverted Tau^{D2} was observed in the AIS, decreasing towards the soma and maintained throughout the experimental period (Figure 2B2 and B4, intensity profiles at $t = 5$ and 30 min; Supplementary Movie S4). This means that once Tau^{D2} is localized in the axon, it cannot return retrogradely to the soma and dendrites. This indicates the presence of a barrier in the AIS, which functions akin to a 'diode' to allow directional entry of Tau from the soma to the axon but not reverse. In fact, photoconversion directly at the AIS also resulted in an anterograde flow of Tau^{D2} towards the distal axon and not towards the soma (Supplementary Figure S2). We also tested the effect of photoconversion of Tau^{D2} in the distal axons, and even after repeated photoconversion the barrier was maintained throughout the experimental period (Supplementary Figure S4).

We asked whether a similar barrier exists between the soma and the dendrites and performed photoconversion in dendrites of a Tau^{D2}-expressing neuron (11 DIV) (Figure 2C1, ROI1). In contrast to axonal Tau, the dendritic Tau^{D2} readily re-entered the somatodendritic compartment and the axon (Figure 2C3). The intensity profiles (Figure 2C2 and C4) indicate that there was no barrier within the somatodendritic compartment (see Supplementary Movie S5). The same effects were observed after photoconversion at the distal ends of dendrites (Supplementary Figure S3). The data demonstrate the unique axonal localization of the barrier mechanism in the AIS to trap Tau once it has entered the axon.

The retrograde barrier depends on microtubules

What cell components are responsible for the retrograde barrier? As Tau is a microtubule-binding protein, we suspected that intact microtubules are one of the requirements. This is indeed the case: once they are depolymerized by nocodazol, the barrier breaks down and allows retrograde axonal flow of Tau^{D2} into the soma (Figure 3A–D; Supplementary Movie S6). This property of a microtubule-based barrier is distinct from the AIS barrier described previously for membrane-associated proteins, characterized by the accumulation of AnkyrinG, β IV-spectrin, ion channels and cell adhesion molecules and F-actin (Winckler *et al*, 1999; Ogawa and Rasband, 2008; Grubb and Burrone, 2010;

Figure 1 Photoconversion of Tau^{Dendra2} in transfected neurons. Top: Bar diagram of human tau40 with domains, phosphorylation sites, and antibody epitopes. The C-terminal half contains the repeat domain (repeats R1–R4, red, R2 alternatively spliced) plus flanking regions (green), responsible for microtubule binding. The N-terminal half (“projection domain”) does not bind to microtubules and contains alternatively spliced inserts I1 and I2 (blue). Major target sites of kinases MARK (KXGS motifs with S262, S293, S324, and S356) and PKA (S214) that control binding of Tau to MT are labelled in red. Seventeen major target sites of proline-directed kinases (in the flanking regions of the repeats and projection domain) and some of the responsible kinases are labelled in green. Epitopes of some phosphorylation-dependent antibodies (12E8, AT8, and PHF1) are indicated. Dendra2 is linked to the N-terminus of Tau as indicated. Bottom: (A) Cortical neuron transfected with Dendra2 for 2 days, showing the green fluorescence before photoconversion. Arrow indicates the axon and arrowhead indicates the somatodendritic compartment. (B) Photoconversion of Dendra2 by UV illumination of the soma (ROI1, boxed in B–D). Images were taken in the red fluorescent channel (B–D) at the indicated time points (0–8 min). (C, D) Time-lapse images trace the rapid redistribution of photoconverted Dendra2 from the soma (ROI1) into the dendrites (arrowhead in D) and the axon (arrow in D). (E) Distribution of Tau^{D2} in a cortical neuron transfected for 2 days before photoconversion. Tau^{D2} appears both in the somatodendritic compartment (arrowheads, top) and in the axon (arrow). (F) Photoconversion of Tau^{D2} by UV illumination of the soma (ROI1, boxed in F–H). (G, H) Time-lapse images in red fluorescent channel trace the redistribution of photoconverted Tau^{D2} from the soma into the dendrites (arrowhead in H) and the axon (arrow in H). Compared with Dendra2 (B–D), the spreading of Tau^{D2} is much slower (images at 0–95 min). The asterisk indicates the non-photoconverted neuron. (I) Intensity versus time in ROI2 in axon (~150 μ m from the soma, red circle in D or H). The signal of Dendra2 reaches a half-maximal level at ~300 s, whereas Tau^{D2} takes much longer (~5300 s). Data shown here are representations of at least three independent experiments.

Rasband, 2010). The AIS components are indeed stable against nocodazol, and therefore cannot account for the retrograde barrier of Tau (Figure 4). Likewise, the barrier of Tau is distinct from the porous filter described by Song *et al* (2009), which blocks axonal access for diffusible molecules greater than ~70 kDa. Their filter is based on F-actin and operates in the anterograde direction, not retrogradely. Our results were confirmed by destroying the actin-based diffusion filter of Song *et al* (2009) in the AIS by latrunculin A

(Supplementary Figure S5), yet the barrier for Tau remained intact (Figure 4G–I). The F-actin staining was significantly reduced after treatment with latrunculin A, including in the AIS (Supplementary Figure S5).

In order to test the spatial relationship of the Tau diffusion barrier with the AIS, we stained the AIS with AnkyrinG after photoconversion in the axon. The data indicate that the classical AIS, as defined by AnkyrinG, and the Tau diffusion barrier overlap significantly. The Tau diffusion barrier is

Figure 2 A barrier mechanism in the initial axon prevents axonal Tau^{D2}, but not Dendra2 alone, from entering the cell body. **(A1–A4)** Time-lapse red fluorescent images of Dendra2 alone (without Tau, **A1**) after photoconversion in the axon in ROI1 (inset in **A1** shows the even overall distribution of Dendra2). The intensity profile **(A2)** corresponds to the fluorescent intensity in ROI2 in the initial axon (between 0 and 50 μm distance from the cell body) at 1 min. Only a low level of Dendra2 has diffused into ROI2, but fluorescence is already visible in the cell body (dashed circle). **(A3, A4)** At 5 min, the level of Dendra2 is increased by diffusion in ROI2, but even more pronounced in the cell body. Only a shallow intensity gradient is observed along ROI2, indicating that there is no barrier for diffusion for Dendra2. **(B1–B4)** A similar experiment was performed by photoconversion in the axon in ROI1 of a neuron transfected with Tau^{D2} (**B1**). The intensity profile of ROI2 at 5 min (**B2**) shows the pronounced gradient of Tau^{D2} in the initial axon, with intensity decaying towards the soma. **(B3, B4)** The gradient is maintained throughout the experimental period (up to 30 min and more) and the intensity in the cell body (dashed circle) remains low, indicating that a barrier in the initial axons (ROI2) prevents the axonal Tau^{D2} from misorting into the cell body. **(C1–C4)** Photoconversion of a dendrite (**C1**) in a neuron transfected with Tau^{D2} (ROI1). The intensity profile in ROI2 at 5 min (**C2**) in the axon emanating from the cell body shows the smooth intensity flow from the somatodendritic compartment into the axon without indication of a barrier. Even at later time points, there is no appearance of a gradient of Tau^{D2} (30 min, **C3, C4**). Data represent at least three independent experiments.

localized within the broad decreasing gradient of the AnkyrinG staining beginning from the axon hillock to the more distal parts of the axon (Supplementary Figure S6).

The retrograde barrier depends on Tau's microtubule affinity and state of phosphorylation

Tau occurs in several isoforms and phospho-variants, and therefore we asked whether all forms of Tau are restrained by the retrograde barrier in the same way, and whether the affinity for microtubules plays a role. This was tested by varying the phosphorylation state of Tau (which in turn alters the affinity for microtubules), or by changing the balance of kinases and phosphatases. The latter is achieved by the phosphatase inhibitor okadaic acid (OA), resulting in a gradual hyperphosphorylation of Tau at multiple sites similar to AD Tau, and loss of MT binding (Lichtenberg-Kraag *et al*, 1992). Figure 5A–C illustrates a neuron with a stable barrier,

but after exposure to 0.5 μM OA at 55 min the barrier breaks down quickly (Figure 5D). The blots (Figure 5E) illustrate that Tau becomes highly phosphorylated at the phospho-epitopes AT8, PHF1, 12E8, and others upon exposure to OA.

In the OA experiment, the phosphorylation of Tau is heterogeneous and includes sites of minor importance for MT binding (e.g., some of the SP or TP motifs). In order to demonstrate a direct and specific relationship between the barrier and the Tau-MT affinity, we transfected Tau^{D2} modified at the four KXGS motifs in the repeat: the '4KXGE' mutant mimics constitutive phosphorylation, whereas the '4KXGA' is non-phosphorylatable at these motifs. The 4KXGE mutant binds to MT only weakly (Biernat and Mandelkow, 1999), and indeed there is no retrograde barrier for this Tau mutant (Figure 6A and B). By contrast, the 4KXGA mutant retains high affinity to MT, and the barrier remains intact (Figure 6C and D). This illustrates that the

Figure 3 The diffusion barrier depends on intact microtubules. (A) Green fluorescent image of an 11 DIV neuron transfected with Tau^{D2} for 2 days before photoconversion. (B) Red fluorescent image of the same neuron immediately after illumination of its axon near the soma (ROI1) with UV light. (C) Time-lapse images up to 30 min show the anterograde diffusion of axonal Tau but retrograde blockage at the initial axon (arrowhead) so that Tau^{D2} does not enter the cell body (dashed circle). At 30 min, cells were treated with 5 μ M nocodazol to disrupt microtubules. (D) After addition of nocodazol, there is diffusion of Tau^{D2} across the barrier in the initial axon (arrowhead) into the somatodendritic compartment (dashed circle). Data represent at least three independent experiments.

barrier depends not on the overall degree of phosphorylation, but on specific phosphorylation sites that detach Tau from microtubules.

The KXGS motifs of Tau, notably S262, are phosphorylated early in neurodegeneration by kinases of the MARK/Par-1 family which play a role in establishing cell polarity (Matenia and Mandelkow, 2009). We, therefore, transfected Tau^{D2} together with MARK2^{CFP}. The kinase became distributed in the cell body, axon, and dendrites (Figure 6E, inset), Tau became strongly phosphorylated at the KXGS motifs (Thies and Mandelkow, 2007), and the barrier indeed broke down, allowing axonal Tau^{D2} to flow into the cell body (Figure 6E). When the same experiment was done with inactive MARK2^{CFP} (with mutations T208A + S212A; Timm *et al*, 2008), Tau remained in a low state of phosphorylation, and the barrier remained intact (Figure 6F). Together, the data show that the retrograde barrier restrains Tau only when its affinity to microtubules is high, but disappears when microtubules break down or when Tau becomes detached by phosphorylation.

In the above experiments, we focused on factors that determine whether a retrograde barrier is present or not. However, the question arises whether there are intrinsic differences in the mobilities of axonal Tau, independent or superimposed on the properties of the barrier. For this purpose, we tested the spreading of photoactivated Tau^{D2}

variants in the anterograde axonal direction. In the initial steady state (~ 2 days after transfection), the cells are homogeneously filled with green fluorescent Tau (Figure 7A). Photoactivation of area ROI1 (~ 50 – 70μ m from the cell body) generates red fluorescence that travels retrogradely until it is stopped by the barrier, but travels anterogradely without interruption (Figure 7B). The rate of migration was measured by the red intensity at ROI2 further downstream (Figure 7C). During the initial 10–20 min the intensity shows a hyperbolic approach to an apparent steady state, consistent with diffusion of Tau^{D2} into ROI2 and beyond whose half time reflects the effective diffusion rate. Comparing half times for different protein species we observed roughly four categories: Dendra2 alone is ‘very fast’ ($t_{1/2} \sim 7$ s), corresponding to a protein that does not interact with microtubules and diffuses freely. Among the Tau species, those binding weakly to MT are ‘fast’, with $t_{1/2} \sim 50$ s (red in Figure 7D). This includes the phospho-mimicking full-length Tau mutants 4KXGE, mutant 214E (mimicking phosphorylation at S214) and 17EP (17 SP/TP motifs turned into EP; Figure 1, top). The ‘slow’ variants, with $t_{1/2}$ around 120–150 s, included wild-type Tau and the 4KXGA mutant, both of which bind well to MT. Finally, there are the ‘ultra-slow’ full-length Tau mutants 17AP (17 SP/TP motifs turned into AP and thus non-phosphorylatable), and 8-repeat-Tau (with duplicated repeat domain), both of which bind tightly to MT (Gustke *et al*, 1994). The data are

Figure 4 The axonal diffusion barrier for Tau coincides with the axon initial segment (AIS) but depends on a different mechanism. (A) Cortical neuron (10 DIV) transfected with Tau^{D2}. Note the even distribution in axon (arrow), soma, and dendrites. (B) Same neuron, fixed and stained for AnkyrinG, a marker of the AIS, (C) merged images. (D) Cortical neuron (10 DIV) transfected with Tau^{D2} and then treated with 10 μM nocodazole. This treatment destroys microtubules but not the localization of AnkyrinG in the AIS (E, F). (G) Green fluorescent image of a neuron (10 DIV) expressing Tau^{D2} and incubated in 2.5 μM latrunculin A for 1 h to disrupt the actin cytoskeleton before photoconversion. (H) Red fluorescent image of the same neuron in the presence of latrunculin A where part of its axon was photoconverted (ROI1) (circles indicate the soma in H and I). (I) Time-lapse image after 75 min showing the blockage at the AIS (arrowhead) for Tau^{D2} in the presence of latrunculin A, indicating that the barrier for Tau does not depend on the actin cytoskeleton.

explained by the diffusion of Tau while it is not bound to MT, which is related to the rates of association and dissociation (k_{on} , k_{off} ; Konzack *et al*, 2007). Here, the important point is that the retrograde barrier is observed only with 'slow' or 'ultra-slow' variants of Tau with tight MT binding, suggesting that the barrier is dominated by kinetic parameters.

When refining this analysis, the comparison of half times measured for Tau spreading proximally or distally from the region of photoconversion (ROI) reveals some directional bias which becomes significant for Tau variants with high MT affinities (4KXGA; 17AP and 8-repeat-Tau). It shows somewhat enhanced spreading to the distal direction (Supplementary Figure S7). The likely explanation is that Tau diffusion is superimposed on (slow) anterograde transport of Tau which is known to depend on binding to microtubules or tubulin oligomers (Baas and Buster, 2004).

Breakdown versus maintenance of the barrier for endogenous and exogenous Tau

One of the enigmas in Tau's behaviour is the apparent contradiction between three key features: (1) At the start of experiments (~7–9 DIV) the neurons are differentiated, and intrinsic Tau is already sorted into axons, suggesting preferential shuttling to the axon and an intact retrograde barrier (consistent with the literature, e.g., Binder *et al*, 1985; Mandell and Banker, 1995). (2) Transfection with exogenous Tau variants, for example, Tau^{D2}, leads to unpolarized distribution into axons, dendrites and cell bodies (e.g., Figures 1E, 3A, and 5A), suggesting that the sorting machinery might

no longer function properly. (3) However, testing axonal Tau directly by photoactivation shows that the retrograde barrier is functional, as described above (e.g., Figure 2).

To clarify this contradiction, we asked if endogenous Tau changes its polarized distribution after transfection with exogenous Tau. In order to distinguish the two types of Tau, we transfected cells with the juvenile isoform (hTau23^{GFP}) lacking the N-terminal inserts and repeat R2 (Tau '0N3R'; Figure 8A). Endogenous rat Tau is a mixture of different isoforms so that some of them can be recognized by antibodies against the first insert (e.g., SA4473, Figure 8B and D). Unexpectedly, the exclusive axonal sorting of endogenous Tau breaks down after transfection of exogenous hTau23^{GFP} so that endogenous Tau now appears in all compartments (Figure 8B). This means that exogenous Tau can induce the missorting of endogenous Tau, while the retrograde barrier is still functional in axons. The effect can be explained by a limited capacity of the axonal sorting machinery, combined with the low degree of phosphorylation of axonal Tau that prevents re-entry into the cell body and dendrites. To minimize possible artefacts of overexpression, we expressed Tau at very low levels by reducing the transfecting virus and/or exposure times up to four-fold. In these conditions, transfected Tau^{D2} could no longer be detected by its fluorescence, but even after antibody amplification with an anti-Dendra2 antibody we could not find physiologically sorted cells with Tau in axons only. At the earliest time point when transfected Tau becomes detectable, it is predominantly present in the cell body and dendrites (Supplementary Figure S8A), but with time it propagates into the axons. We quantified the axonal spreading on the basis of the fluorescent front

Figure 5 Hyperphosphorylation by okadaic acid (OA) treatment allows Tau^{D2} to pass the barrier. **(A)** Green fluorescent image of a 9 DIV neuron expressing Tau^{D2} before photoconversion. **(B)** Red fluorescent image of the same neuron where part of its axon was photoconverted (ROI1). Time-lapse image after 20 min showing the anterograde spreading of Tau^{D2} but blockage at the AIS near the cell body (arrowheads in **B–D** indicate the AIS). **(C)** The same protocol of photoconversion as in **(B)** was repeated in the same axonal region (ROI1) 55 min after the first illumination; at this time, 500 nM OA was added. The diffusion barrier at the AIS is still visible (arrowhead). **(D)** Redistribution of axonal Tau to the somatodendritic compartment after OA treatment. Increasing fluorescence intensity in the soma is observed shortly after addition of OA, and the gradient in distribution of axonal Tau in the AIS disappears. Dashed circles indicate the soma in **(B–D)**. **(E)** Western blot of extracts of cortical neurons (11 DIV) treated with OA (500 nM, 1 h) using phosphorylation-dependent Tau antibodies AT8, PHF1, and 12E8. The signals of hyperphosphorylated Tau increase strongly after phosphatases are inhibited by OA treatment (right lanes), especially in the case of 12E8 (pS262/pS356 in the repeats, right panel); whereas in the untreated cells the signals of phosphorylated Tau at these epitopes remain low (left lanes). Note the clear upward shift of the bands of phosphorylated Tau in the OA-treated cells. A blot with anti-actin antibody was used as loading control.

(following Utton *et al*, 2002) and fitted it with a square root function as described (Konzack *et al*, 2007), consistent with the assumption that the spreading in our regime of time and distance is dominated by diffusion (Supplementary Figure S8B). However, even at very low expression levels of Tau^{D2} the endogenous Tau became missorted into the somatodendritic compartment, suggesting that the capacity of sorting is readily overwhelmed.

It is noteworthy that the missorting of Tau at elevated levels does not affect the sorting of the somatodendritic MAP2 (Figure 8C), in spite of its Tau-like microtubule-binding domain. This argues that the two proteins are constrained by different mechanisms (e.g., MAP2 would be too large to pass through the porous anterograde filter; Nakata and Hirokawa, 2003; Song *et al*, 2009).

Discussion

This study was motivated by the observation that Tau is sorted into axons of mature healthy neurons, whereas it acquires a somatodendritic distribution in Alzheimer's disease and other tauopathies (Binder *et al*, 1985). This raises the questions of how Tau becomes axonal in the first place, how the neuron makes the transition from the immature state (with ubiquitous Tau distribution) to the mature state, and why the sorting mechanism breaks down during neurodegeneration.

Several authors have addressed the problem of sorting of axonal Tau, dendritic MAP2, and other MAPs during neuronal polarization (Binder *et al*, 1985; Kosik and Finch, 1987; Hirokawa *et al*, 1996; Aronov *et al*, 2001). These studies established that the bulk of Tau is indeed restricted to axons

Figure 6 Effect of pseudo-phosphorylation of Tau^{D2} and MARK activity on axonal Tau redistribution and diffusion barrier. (A, B) Cortical neuron transfected with pseudo-phosphorylated Tau^{D2}-4KXGE (at all four KXGS → E motifs in the repeat domain, thus weakening the binding to microtubules). After photoconversion in the axon at time $t = 0$ (ROI1 in A) the soma (dashed circles) lights up in a time-dependent manner, indicating that loss of microtubule-binding enables Tau^{D2}-4KXGE to pass the retrograde diffusion barrier between the axon and the cell body. The inset in (A) shows the green fluorescent image of the neuron before photoconversion. (C, D) Similar experiment to (A, B) performed in neurons transfected with Tau^{D2}-4KXGA (non-phosphorylatable in the repeat domain and therefore tightly binding to microtubules). ROI1 in (C) indicates the axonal region for UV illumination. There is no retrograde flow of Tau^{D2}-4KXGA into the soma of the neuron (D, 30 min). (E) Time-lapse images taken in the red fluorescent channel at 1 h after photoconversion in the axon (ROI1) of a neuron co-transfected with CFP-MARK2 and Tau^{D2}. Note that the soma shows strong fluorescence since the phosphorylated Tau^{D2}, not bound to microtubules, can pass the barrier. The intensity profile of the AIS (ROI2 in E) (inset) shows no gradient of Tau distribution in this region, indicating that Tau^{D2} can pass through the barrier after phosphorylation by MARK2. (F) Same experimental procedure as in (E), performed in a neuron co-transfected with the inactive mutant CFP-MARK2^{T208A + S212A} and Tau^{D2}. ROI1 indicates the axonal region for UV illumination. The fluorescent intensity in the somatodendritic compartment remains low compared with (E), indicating that the kinase-dead mutant of MARK could not phosphorylate Tau^{D2} at the KXGS motifs in the repeat domain, and therefore Tau^{D2} still binds strongly to microtubules and cannot pass the barrier. The intensity profile in the AIS (ROI2 in F) (inset) shows the gradient of Tau^{D2} typical of an intact barrier. Data represent at least three independent experiments.

in mature neurons, even though minor amounts might occur in other compartments, for example, in dendrites (Papazomenos and Binder, 1987; Ittner *et al*, 2010), the nucleus (Sultan *et al*, 2011), or in other cell types (notably oligodendrocytes; LoPresti *et al*, 1995; Klein *et al*, 2002). The emerging picture for axonal Tau sorting is that there are several overlapping mechanisms, rather than a single one. On the level of mRNA, the 3'UTR contains a zip code that directs it into the axon for local translation (Aronov *et al*, 2001). The 5' UTR contains a terminal oligopyrimidine tract which enhances translation of Tau in axons under control of mTOR (Morita and Sobue, 2009). On the level of Tau protein, sorting could be achieved by a combination of selective transport, barriers, phosphorylation, and degradation. For

example, Tau can be transported into the axon while MAP2 is excluded from it, a given MAP is more readily degraded if it appears in the 'wrong' compartment, and selective transport can occur along microtubules through special combinations of motors, adaptors, and tubulin modifications (Hirokawa *et al*, 1996; Nakata and Hirokawa, 2003; Hirokawa and Takemura, 2005; Konishi and Setou, 2009). The long-haul transport mechanisms tend to be microtubule based because they form extended tracks for vesicles, organelles, and nucleoprotein complexes (Stokin and Goldstein, 2006; Hirokawa *et al*, 2010), whereas known barriers such as the AIS are based on F-actin filaments because they can form meshworks, for example, for membrane-associated components (Ogawa and Rasband, 2008; Song *et al*, 2009).

Figure 7 Anterograde axonal diffusion of Tau depends on phosphorylation and binding to microtubules. (A) Green fluorescent image of a cortical neuron expressing Tau^{D2}, before photoconversion. A region of $55 \times 35 \mu\text{m}^2$ containing a $65 \mu\text{m}$ stretch of the axon (ROI1 in B) and lying at a $50\text{--}70 \mu\text{m}$ distance from the soma is chosen for photoconversion. (B) Red fluorescent image of the same neuron at 15 min after photoconversion. ROI2 is selected for intensity integration ($30 \mu\text{m}$ segment of the axon, at $10 \mu\text{m}$ distance to ROI 1). Note that Tau^{D2} diffuses rapidly in the anterograde direction, but is restrained towards the cell body (dashed circle). (C) Intensity in ROI2 versus time (0 = time of photoconversion), rising with a half time of $t_{1/2} \sim 150$ s which reflects the effective rate of Tau diffusion in the anterograde direction. (D) Half times of spreading of different Tau variants tagged with Dendra2 ($n \geq 3$ cells each; error bars indicate s.e.). Note that Dendra2 alone diffuses rapidly ($t_{1/2} \sim 7$ s). Tau wild type and tightly binding non-phosphorylatable mutants 4KXGA and 17AP diffuse slowly ($t_{1/2} \sim 130$ to 220 s), whereas phospho-mimicking mutants binding weakly to microtubules (4KXGE, 214E, and 17EP) and diffuse more rapidly ($t_{1/2} \sim 70$ s). The strongly binding mutant with duplicated repeats (8R-Tau) diffuses very slowly ($t_{1/2} \sim 260$ s). ** $P < 0.01$ and * $P < 0.05$.

In the case of Tau, we are faced with several seemingly contradictory observations:

- Tau is associated with microtubules, yet it diffuses fairly rapidly (Samsonov *et al*, 2004; Konzack *et al*, 2007). This can be explained by the short dwell time of Tau on microtubules. However, by this argument one cannot explain why Tau is mostly restricted to axons.
- In immature axons, Tau is ubiquitous in the cytoplasm. During differentiation, the Tau level rises several fold (Drubin and Kirschner, 1986), yet Tau becomes axonally restricted. This could be explained because the high initial state of phosphorylation (~ 4 Pi per molecule) drops to the normal low adult levels (~ 2 Pi; Kopke *et al*, 1993), and the isoforms shift from small (fetal, 3R-Tau) to a mix of larger 4-repeat isoforms (Goedert *et al*, 1989; Kosik *et al*, 1989). These features argue for a tighter binding of adult Tau to microtubules, coincident with increased microtubule stabilization.
- Nevertheless, the axonal sorting of Tau during differentiation is in stark contrast to the missorting after microinjection or transfection of Tau (which causes even missorting of endogenous Tau, Figure 8, and missorting is already present at extremely low expression levels detectable only via antibody amplification

of transfected Tau; Supplementary Figure S8A). A plausible interpretation is that the Tau sorting machinery is readily overwhelmed by elevated Tau, such that even very low levels of additional Tau suffice for impairing the tight and precise sorting machinery of Tau.

How can we reconcile the observations on Tau sorting with the mechanisms described in the literature so far? Three major modes of selection have been described: (a) There is a diffusion barrier for membrane-associated components in the AIS, based on F-actin but not on microtubules (Rasband, 2010). (b) There is an anterograde diffusion barrier for cytoplasmic components greater than ~ 70 kDa (Song *et al*, 2009), also dependent on F-actin but not on microtubules. (c) There is active, microtubule, and motor-based transport of selected cargoes that can overcome the F-actin-dependent barriers. How does this apply to Tau? Since the bulk of Tau is not membrane-associated, option (a) does not apply. Since Tau is smaller than 70 kDa, the cytoplasmic pore filter does not apply either, consistent with the observation that Tau can readily diffuse into axons (Konzack *et al*, 2007). Third, Tau and other axonal MAPs (e.g., MAP1b) can be transported into axons by long-haul microtubule-based transport, piggy backing on microtubular structures (Baas and Buster, 2004). This

Figure 8 Transfection of neurons with Tau^{GFP} causes missorting of both exogenous and endogenous Tau. (A) Cortical neuron (7 DIV) transfected with hTau23^{GFP} lacking the two N-terminal inserts (see Figure 1, top). The exogenous Tau distributes into all compartments (axon indicated with arrows in A–C, dendrites indicated with arrowheads in A–C, soma), similar to the longest isoform used above. (B) Cells were stained with antibody SA4473 against the first insert, present only in endogenous Tau but not in the transfected Tau. The antibody stains not only axons but all compartments, indicating that the transfection of exogenous Tau leads to the missorting of endogenous and exogenous Tau. (C) Same field stained with MAP2 as a marker of soma and dendrites, illustrating that MAP2 maintains its normal sorting. (D) Blot showing that exogenous hTau40^{D2} is recognized by antibody SA4473 against the first insert, but hTau23^{GFP} is not recognized, confirming the specificity of this antibody. Endogenous Tau is recognized in both cases. Actin is shown as a loading control.

system is apparently able to carry almost all endogenous Tau into the axon, leaving only trace amounts in dendrites.

How is this polarized distribution maintained, vis-a-vis the high mobility of Tau by diffusion? Our experiments argue that there is a novel type of retrograde filter, also located in the AIS but dependent on microtubules, not on F-actin. Thus, Tau can move into the axon, but not out. What conditions are necessary for the filter to work? First, Tau must be able to bind to microtubules, because Tau phosphorylated at critical sites, which disrupt microtubule binding can bypass the barrier. Second, microtubules must be intact, because disassembly by nocodazole destroys the retrograde Tau barrier (but not the F-actin-based AIS barrier). Significantly, excess Tau (by transfection) can overwhelm the anterograde sorting machinery, but does not destroy the retrograde barrier.

The results suggest answers to an important question in Tau research: where does the missorted dendritic Tau come from in neurodegeneration? One possibility is that Tau synthesized in the cell body is not axonally sorted because the sorting machinery has broken down, so that the dendritic Tau would come straight from the cell body. However, our experiments show that even axonal Tau can transit directly past the barrier into dendrites, once it is hyperphosphorylated. This places a new importance on Tau phosphorylation which causes detachment from microtubules: a perturbed balance of kinase/phosphatase activities in the axon can make the retrograde barrier leaky and promote accumulation of Tau in dendrites, where it can aggregate into PHFs.

What is the molecular basis of the retrograde barrier? One could think of several possibilities:

- (i) A (passive) size exclusion filter (analogous to the filter described by Song *et al*, 2009)—this is unlikely because it would not discriminate between different states of phosphorylation. Conversely, the data imply that the mechanism involves some preferential interaction of Tau regulated by phosphorylation.
- (ii) A barrier imposed by preferential binding to the F-actin meshwork in the AIS—also unlikely because the barrier remains active even when F-actin is depolymerized (Figure 4).
- (iii) Preferential interactions with microtubules in the AIS—this would be partly consistent with the observations that only Tau with high microtubule affinity is restrained by the barrier. However, this model requires further assumptions. One is that microtubules in the AIS must be different from the remainder of the axon, which is indeed the case. The microtubules in the AIS are selectively modified and differ in their dynamics (Nakata and Hirokawa, 2003; Konishi and Setou, 2009; Sanchez-Ponce *et al*, 2011). A problem with this model is that trapping of Tau on microtubules of the AIS would lead to a local accumulation of Tau, contrary to the observations. One way to remove this dilemma is to postulate that trapped Tau is continuously swept forward into the axon by slow anterograde transport of Tau-tubulin complexes (Baas and Buster, 2004). This

phenomenon could explain the observation that Tau constructs with high affinity for microtubules have a preference for anterograde over retrograde propagation (Supplementary Figure S7).

- (iv) The neurofilament meshwork could provide a further preferential trap for Tau. Although neurofilaments are also mobile and move down axons in a stop-and-go fashion (Wang *et al*, 2000), the meshwork in the AIS of mature neurons is particularly static and dense due to their extended sidearms (Hirokawa, 1982; Yuan *et al*, 2009). Neurofilaments interact with microtubules, which would be consistent with the dependence of the retrograde barrier on intact microtubules (Figure 3). We have carried out computational modelling (not shown) to confirm that a combination of these factors would suffice to explain the 'diode' effect of Tau distribution. In this case, the barrier exerts its function through differential binding affinities for several cytoskeleton components.

Materials and methods

Plasmids construction

pDendra2-C vector was purchased from Evrogen and cDNA of human full-length Tau was subcloned into the C-terminal of Dendra2. The cDNA of Dendra2-Tau (termed Tau^{D2}) was then subcloned into the pShuttle vector under control of the human cytomegalovirus (CMV) promoter. The *SfiI*-*NheI* fragments containing parts of the cDNAs of Tau-S214E, pseudo-phosphorylated Tau-4KXGE (Ser to Glu at all four KXGS motifs in the repeat domain), non-phosphorylatable Tau-4KXGA (Ser to Ala at all four KXGS motifs in the repeat domain), Tau-17EP (Ser/Thr to Glu at all SP/TP sites in the flanking region), Tau-17AP (Ser/Thr to Ala at all SP/TP sites in the flanking region) and Tau-8-repeat (Tau without N-terminal inserts and including a duplicated insertion of the four repeats; Gustke *et al*, 1994) were subcloned into the respective restriction sites of the pShuttle-CMV vector containing Dendra2-Tau. The cloning of CFP-MARK2 and its inactive mutant CFP-MARK2-T208A/S212A was reported previously (Timm *et al*, 2008). All plasmids were verified by restriction analysis and DNA sequencing.

Cell culture and transfection

Dissociated cortical neurons were prepared from embryonic day 18 (E18) Sprague Dawley rats according to Banker and Goslin (1988) and plated on poly-D-lysine (50 µg/ml)-coated cover glass at a density of 1×10^5 cells/cm². After 4 days, 0.5 µM cytosine arabinoside (Sigma, Munich, Germany) was added to the cultures to reduce glial growth. Cultures were maintained in NeuroBasal medium with B27 (Invitrogen) at 37°C, 5% CO₂, and 100% relative humidity for 7–9 days. Transfection with the plasmids was carried out with Lipofectamine 2000 (Invitrogen). Expression was allowed for 48–72 h.

Immunostaining

Primary cortical neurons were fixed at indicated experimental time with 3.7% paraformaldehyde (Sigma) for 15 min at room temperature and washed with PBS. Cells were then permeabilized with 80% methanol at –20°C for 5 min. This was followed by blocking with 10% goat serum for 30 min at 37°C. After incubation with primary antibodies for 1 h at 37°C, cells were washed with PBS and labelled with secondary antibodies for 1 h at 37°C. The following antibodies were used: monoclonal anti-MAP2 (2a + 2b) (AP20) (Sigma) (1:300), monoclonal anti-AnkyrinG (Invitrogen) (1:300), polyclonal SA4473 against tau N-terminal inserts (1:100), polyclonal anti-Dendra2 (Evrogen) (1:500), fluorescently labelled secondary

antibodies FITC or TRITC against mouse (1:200), and Cy5 against rabbit (1:200) were from Dianova (Hamburg, Germany).

Imaging, photoconversion, and analysis

A Fluoview1000 confocal microscope (Olympus, Hamburg, Germany) equipped with a SIM scanner (which allows for simultaneous stimulation and imaging) and a $\times 60$ objective live-cell imaging chamber and ZDC system for Z-drift compensation was used for photoconversion experiments and image acquisition. For time-lapse live-cell imaging, cells were plated on glass bottom dishes and were kept in the imaging chamber (37°C, 65% humidity and supplied with 5% CO₂). Images were taken every 10 s for the calculation of axonal Tau distribution rate; every 20 s for other applications. Before photoconversion, green fluorescence of Dendra2 was acquired by excitation at 488 nm and detection over the range of 500–550 nm. Photoconversion was performed during the imaging interval by rapidly illuminating the selected area with a 405-nm laser scanner (3–4 exposures of 0.3 s each). Thereafter, red fluorescence was acquired by excitation at 561 nm and detection over the range 570–670 nm. Fluorescence intensity profiles and values according to the indicated time points and area were determined by the microscopy software. Microscopic settings as well as the selection of the regions of interest were kept similar in order to allow comparison between different experiments, for example, region for photoconversion of Tau^{D2} ROI1 = $55 \times 35 \mu\text{m}^2$ containing a 65-µm stretch of the axon and lying at a 50–70-µm distance from the soma, region ROI2 for observing translocated Tau^{D2} = 30 µm segment of the axon $\sim 10 \mu\text{m}$ away from ROI1 (see e.g., Figure 7). Ratiometric analysis was carried out by taking the ratio of red/green channel after photoconversion in the region of interest (ROI), with the aid of Metamorph Software. Identification, imaging, and analysis of photoconverted cells after AnkyrinG staining, and Tau propagation analysis after different transfection periods was done using a Leica DMI 4000 B Metamorph-based microscope equipped with an HQCoolSnap2 camera.

Western blotting

Proteins were separated onto SDS gels and electrotransferred onto polyvinylidene difluoride membranes by semi-dry blotting (1 mA/cm², 1 h). The membranes were blocked with 5% non-fat dry milk in $1 \times$ Tris-buffered saline with 0.1% Tween-20 (TBST) for 1 h at room temperature and then treated with the selected primary antibody (12E8 1:1000, Elan Pharmaceuticals; PHF1 1:500, gift from Peter Davies; AT8 1:500, Thermo Scientific; β -actin 1:1000, Sigma) in $1 \times$ TBST at 37°C for 1 h. The membranes were washed three times with $1 \times$ TBST. The corresponding secondary antibody in $1 \times$ TBST was added, and the membranes were incubated at 37°C for 45 min followed by washing with $1 \times$ TBST (three times). The substrate reaction was carried out with ECL detection reagents (GE Healthcare) and visualized using the LAS 3000 system (Raytest).

Acknowledgements

We thank Annika Eikhof and Ilka Lindner for excellent technical assistance and Alexander Marx for help with statistical analysis. The project was supported by grants from EU (FP7-Memosad), BMBF (KNDD), DFG (FOR629), Breuer Foundation and Metlife Foundation.

Author contributions: XL and EMM designed the study; XL performed experiments; JB supplied Tau plasmids; XL, EMM, and EM analysed the data; XL, EMM and EM wrote the paper. HZ and YK conducted experiments for the revisions of the manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

References

- Aronov S, Aranda G, Behar L, Ginzburg I (2001) Axonal tau mRNA localization coincides with tau protein in living neuronal cells and depends on axonal targeting signal. *J Neurosci* **21**: 6577–6587
- Aronov S, Aranda G, Behar L, Ginzburg I (2002) Visualization of translated tau protein in the axons of neuronal P19 cells and characterization of tau RNP granules. *J Cell Sci* **115**: 3817–3827

- Baas PW, Buster DW (2004) Slow axonal transport and the genesis of neuronal morphology. *J Neurobiol* **58**: 3–17
- Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. *Nat Rev Neurosci* **8**: 663–672
- Banker G, Goslin K (1988) Developments in neuronal cell culture. *Nature* **336**: 185–186
- Biernat J, Mandelkow EM (1999) The development of cell processes induced by tau protein requires phosphorylation of serine 262 and 356 in the repeat domain and is inhibited by phosphorylation in the proline-rich domains. *Mol Biol Cell* **10**: 727–740
- Binder LI, Frankfurter A, Rebhun LI (1985) The distribution of tau in the mammalian central nervous system. *J Cell Biol* **101**: 1371–1378
- Burack MA, Silverman MA, Banker G (2000) The role of selective transport in neuronal protein sorting. *Neuron* **26**: 465–472
- Coleman PD, Yao PJ (2003) Synaptic slaughter in Alzheimer's disease. *Neurobiol Aging* **24**: 1023–1027
- Drubin D, Kirschner M (1986) Purification of tau protein from brain. *Methods Enzymol* **134**: 156–160
- Garner CC, Brugg B, Matus A (1988) A 70-kilodalton microtubule-associated protein (MAP2c), related to MAP2. *J Neurochem* **50**: 609–615
- Gauthier A, Brandt R (2010) Live cell imaging of cytoskeletal dynamics in neurons using fluorescence photoactivation. *Biol Chem* **391**: 639–643
- Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA (1989) Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. *EMBO J* **8**: 393–399
- Grubb MS, Burrone J (2010) Building and maintaining the axon initial segment. *Curr Opin Neurobiol* **20**: 481–488
- Gurskaya NG, Verkhusha VV, Shcheglov AS, Staroverov DB, Chepurnykh TV, Fradkov AF, Lukyanov S, Lukyanov KA (2006) Engineering of a monomeric green-to-red photoactivatable fluorescent protein induced by blue light. *Nat Biotechnol* **24**: 461–465
- Gustke N, Trinczek B, Biernat J, Mandelkow EM, Mandelkow E (1994) Domains of tau protein and interactions with microtubules. *Biochemistry* **33**: 9511–9522
- Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. *Nat Rev Mol Cell Biol* **8**: 101–112
- Hirokawa N (1982) Cross-linker system between neurofilaments, microtubules, and membranous organelles in frog axons revealed by the quick-freeze, deep-etching method. *J Cell Biol* **94**: 129–142
- Hirokawa N, Funakoshi T, Sato-Harada R, Kanai Y (1996) Selective stabilization of tau in axons and microtubule-associated protein 2C in cell bodies and dendrites contributes to polarized localization of cytoskeletal proteins in mature neurons. *J Cell Biol* **132**: 667–679
- Hirokawa N, Niwa S, Tanaka Y (2010) Molecular motors in neurons: transport mechanisms and roles in brain function, development, and disease. *Neuron* **68**: 610–638
- Hirokawa N, Takemura R (2005) Molecular motors and mechanisms of directional transport in neurons. *Nat Rev Neurosci* **6**: 201–214
- Itnner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufienbiel M, Hardeman E, Gotz J (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. *Cell* **142**: 387–397
- Klein C, Kramer EM, Cardine AM, Schraven B, Brandt R, Trotter J (2002) Process outgrowth of oligodendrocytes is promoted by interaction of fyn kinase with the cytoskeletal protein tau. *J Neurosci* **22**: 698–707
- Kole MH, Ilschner SU, Kampa BM, Williams SR, Ruben PC, Stuart GJ (2008) Action potential generation requires a high sodium channel density in the axon initial segment. *Nat Neurosci* **11**: 178–186
- Konishi Y, Setou M (2009) Tubulin tyrosination navigates the kinesin-1 motor domain to axons. *Nat Neurosci* **12**: 559–567
- Konzack S, Thies E, Marx A, Mandelkow EM, Mandelkow E (2007) Swimming against the tide: mobility of the microtubule-associated protein tau in neurons. *J Neurosci* **27**: 9916–9927
- Kopke E, Tung YC, Shaikh S, Alonso AC, Iqbal K, Grundke-Iqbal I (1993) Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. *J Biol Chem* **268**: 24374–24384
- Kosik KS, Finch EA (1987) MAP2 and tau segregate into dendritic and axonal domains after the elaboration of morphologically distinct neurites: an immunocytochemical study of cultured rat cerebrum. *J Neurosci* **7**: 3142–3153
- Kosik KS, Orecchio LD, Bakalis S, Neve RL (1989) Developmentally regulated expression of specific tau sequences. *Neuron* **2**: 1389–1397
- Lazarov O, Morfini GA, Pigino G, Gadadhar A, Chen X, Robinson J, Ho H, Brady ST, Sisodia SS (2007) Impairments in fast axonal transport and motor neuron deficits in transgenic mice expressing familial Alzheimer's disease-linked mutant presenilin 1. *J Neurosci* **27**: 7011–7020
- Ledesma MD, Dotti CG (2003) Membrane and cytoskeleton dynamics during axonal elongation and stabilization. *Int Rev Cytol* **227**: 183–219
- Lichtenberg-Kraag B, Mandelkow EM, Biernat J, Steiner B, Schroter C, Gustke N, Meyer HE, Mandelkow E (1992) Phosphorylation-dependent epitopes of neurofilament antibodies on tau protein and relationship with Alzheimer tau. *Proc Natl Acad Sci USA* **89**: 5384–5388
- LoPresti P, Szuchet S, Papasozomenos SC, Zinkowski RP, Binder LI (1995) Functional implications for the microtubule-associated protein tau: localization in oligodendrocytes. *Proc Natl Acad Sci USA* **92**: 10369–10373
- Mandell JW, Banker GA (1995) The microtubule cytoskeleton and the development of neuronal polarity. *Neurobiol Aging* **16**: 229–237; discussion 238
- Matenia D, Mandelkow EM (2009) The tau of MARK: a polarized view of the cytoskeleton. *Trends Biochem Sci* **34**: 332–342
- Mattson MP (2004) Pathways towards and away from Alzheimer's disease. *Nature* **430**: 631–639
- Migheli A, Butler M, Brown K, Shelanski ML (1988) Light and electron microscope localization of the microtubule-associated tau protein in rat brain. *J Neurosci* **8**: 1846–1851
- Morita T, Sobue K (2009) Specification of neuronal polarity regulated by local translation of CRMP2 and Tau via the mTOR-p70S6K pathway. *J Biol Chem* **284**: 27734–27745
- Nakada C, Ritchie K, Oba Y, Nakamura M, Hotta Y, Iino R, Kasai RS, Yamaguchi K, Fujiwara T, Kusumi A (2003) Accumulation of anchored proteins forms membrane diffusion barriers during neuronal polarization. *Nat Cell Biol* **5**: 626–632
- Nakata T, Hirokawa N (2003) Microtubules provide directional cues for polarized axonal transport through interaction with kinesin motor head. *J Cell Biol* **162**: 1045–1055
- Ogawa Y, Rasband MN (2008) The functional organization and assembly of the axon initial segment. *Curr Opin Neurobiol* **18**: 307–313
- Papasozomenos SC, Binder LI (1987) Phosphorylation determines two distinct species of Tau in the central nervous system. *Cell Motil Cytoskeleton* **8**: 210–226
- Pimplikar SW, Nixon RA, Robakis NK, Shen J, Tsai LH (2010) Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. *J Neurosci* **30**: 14946–14954
- Rasband MN (2010) The axon initial segment and the maintenance of neuronal polarity. *Nat Rev Neurosci* **11**: 552–562
- Roberson ED, Searce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. *Science* **316**: 750–754
- Samsonov A, Yu JZ, Rasenick M, Popov SV (2004) Tau interaction with microtubules *in vivo*. *J Cell Sci* **117**: 6129–6141
- Sanchez-Ponce D, Munoz A, Garrido JJ (2011) Casein kinase 2 and microtubules control axon initial segment formation. *Mol Cell Neurosci* **46**: 222–234
- Scott DA, Das U, Tang Y, Roy S (2011) Mechanistic logic underlying the axonal transport of cytosolic proteins. *Neuron* **70**: 441–454
- Song AH, Wang D, Chen G, Li Y, Luo J, Duan S, Poo MM (2009) A selective filter for cytoplasmic transport at the axon initial segment. *Cell* **136**: 1148–1160
- Stokin GB, Goldstein LS (2006) Axonal transport and Alzheimer's disease. *Annu Rev Biochem* **75**: 607–627
- Sultan A, Nesslany F, Violet M, Begard S, Loyens A, Talahari S, Mansuroglu Z, Marzin D, Sergeant N, Humez S, Colin M, Bonnefoy E, Buee L, Galas MC (2011) Nuclear tau, a key player in neuronal DNA protection. *J Biol Chem* **286**: 4566–4575

- Thies E, Mandelkow EM (2007) Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. *J Neurosci* **27**: 2896–2907
- Timm T, Balusamy K, Li X, Biernat J, Mandelkow E, Mandelkow EM (2008) Glycogen synthase kinase (GSK) 3 β directly phosphorylates Serine 212 in the regulatory loop and inhibits microtubule affinity-regulating kinase (MARK) 2. *J Biol Chem* **283**: 18873–18882
- Utton MA, Connell J, Asuni AA, van Slegtenhorst M, Hutton M, de Silva R, Miller CC, Anderton BH (2002) The slow axonal transport of the microtubule-associated protein tau and the transport rates of different isoforms and mutants in cultured neurons. *J Neurosci* **22**: 6394–6400
- Wang L, Ho CL, Sun D, Liem RK, Brown A (2000) Rapid movement of axonal neurofilaments interrupted by prolonged pauses. *Nat Cell Biol* **2**: 137–141
- Weissmann C, Reyher HJ, Gauthier A, Steinhoff HJ, Junge W, Brandt R (2009) Microtubule binding and trapping at the tip of neurites regulate tau motion in living neurons. *Traffic* **10**: 1655–1668
- Winckler B, Forscher P, Mellman I (1999) A diffusion barrier maintains distribution of membrane proteins in polarized neurons. *Nature* **397**: 698–701
- Witte H, Bradke F (2008) The role of the cytoskeleton during neuronal polarization. *Curr Opin Neurobiol* **18**: 479–487
- Yuan A, Sasaki T, Rao MV, Kumar A, Kanumuri V, Dunlop DS, Liem RK, Nixon RA (2009) Neurofilaments form a highly stable stationary cytoskeleton after reaching a critical level in axons. *J Neurosci* **29**: 11316–11329
- Zempel H, Thies E, Mandelkow E, Mandelkow EM (2010) Abeta oligomers cause localized Ca²⁺ elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. *J Neurosci* **30**: 11938–11950